Potassium channel blockers as an effective treatment to restore impulse conduction in injured axons

Neuroscience Bulletin

Volumn 27, Issue 1, 2011, Pages 36-44

  Shi, Riyi ^a   Sun, Wenjing ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

4 aminopyridine; axon; conduction; demyelination; injury; potassium channel

Indexed keywords

4 AMINOPYRIDINE; 4 AMINOPYRIDINE 3 METHANOL; CARBAMIC ACID METHYL ESTER; ION TRANSPORT AFFECTING AGENT; MYELIN; N (4 PYRIDYL)ETHYL CARBAMATE; N (4 PYRIDYL)METHYL CARBAMATE; N (4 PYRIDYL)TERTBUTYL; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

AXONAL INJURY; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; HUMAN; MULTIPLE SCLEROSIS; MYELINATED NERVE; NERVE CONDUCTION; NONHUMAN; REFRACTORY PERIOD; SHORT SURVEY; SPINAL CORD INJURY;

4-AMINOPYRIDINE; ANIMALS; AXONS; DEMYELINATING DISEASES; HUMANS; NEURAL CONDUCTION; POTASSIUM CHANNEL BLOCKERS;

EID: 79952552151     PISSN: 16737067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12264-011-1048-y     Document Type: Short Survey

References (74)

1. Kandel ER, Schwartz JH, Jessell TM. Principles of Neural Science. 4th ed. New York: McGraw-hill, 2000.
2. Waxman SG, Kocsis JD, Stys PK. The Axon. New York Oxford: Oxford University Press, 1995.
3. Blight AR. Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. Central Nervous System Trauma 1985, 2: 299-315. (Pubitemid 16083165)
4. Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997, 77: 553-562. (Pubitemid 27079623)
5. Nashmi R, Fehlings MG. Changes in axonal physiology and morphology after chronic compressive injury of the rat thoracic spinal cord. Neuroscience 2001, 104: 235-251. (Pubitemid 32322628)
6. Waxman SG. Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 1982, 306: 1529-1533. (Pubitemid 12123934)
7. Waxman SG. Demyelinating diseases - new pathological insights, new therapeutic targets. N Engl J Med 1998, 338: 323-325. (Pubitemid 28065260)
8. Waxman SG. Ion channels and neuronal dysfunction in multiple sclerosis. Arch Neurol 2002, 59: 1377-1380. (Pubitemid 35014801)
9. Jensen JM, Shi R. Effects of 4-aminopyridine on stretched mammalian spinal cord: the role of potassium channels in axonal conduction. J Neurophysiol 2003, 90: 2334-2340. (Pubitemid 37266501)
10. Sun W, Smith D, Fu Y, Cheng JX, Bryn S, Borgens R, et al. Novel potassium channel blocker, 4-AP-3-MeOH, inhibits fast potassium channels and restores axonal conduction in injured guinea pig spinal cord white matter. J Neurophysiol 2010, 103: 469-478.
11. Waxman SG, Ritchie JM. Molecular dissection of the myelinated axon. Ann Neurol 1993, 33: 121-136. (Pubitemid 23039921)
12. Poliak S, Peles E. The local differentiation of myelinated axons at nodes of Ranvier. Nat Rev Neurosci 2003, 4: 968-980. (Pubitemid 37486673)
13. Vabnick I, Trimmer JS, Schwarz TL, Levinson SR, Risal D, Shrager P. Dynamic potassium channel distributions during axonal development prevent aberrant firing patterns. J Neurosci 1999, 19: 747-758. (Pubitemid 29036026)
14. Zhou L, Zhang CL, Messing A, Chiu SY. Temperature-sensitive neuromuscular transmission in Kv1.1 null mice: role of potassium channels under the myelin sheath in young nerves. J Neurosci 1998, 18: 7200-7215. (Pubitemid 28425807)
15. Chiu SY. Asymmetry currents in the mammalian myelinated nerve. J Physiol 1980, 309: 499-519. (Pubitemid 11199955)
16. Chiu SY, Ritchie JM. On the physiological role of internodal potassium channels and the security of conduction in myelinated nerve fibres. Proc R Soc Lond B Biol Sci 1984, 220: 415-422. (Pubitemid 14159702)
17. Peles E, Salzer JL. Molecular domains of myelinated axons. Curr Opin Neurobiol 2000, 10: 558-565.
18. Salzer JL, Brophy PJ, Peles E. Molecular domains of myelinated axons in the peripheral nervous system. Glia 2008, 56: 1532-1540.
19. Ouyang H, Sun W, Fu Y, Li J, Cheng JX, Nauman E, et al. Compression induces acute demyelination and potassium channel exposure in spinal cord. J Neurotrauma 2010, 27: 1109-1120.
20. Shi R, Kelly TM, Blight AR. Conduction block in acute and chronic spinal cord injury: Different dose-response characteristics for reversal by 4-Aminopyridine. Exp Neurology 1997, 148: 495-501. (Pubitemid 28068844)
21. Waxman SG. Demyelination in spinal cord injury and multiple sclerosis: what can we do to enhance functional recovery? J Neurotrauma 1992, 9: S105-117.
22. Blight AR. Morphometric analysis of a model of spinal cord injury in guinea pigs, with behavioral evidence of delayed secondary pathology. J Neurol Sci 1991, 103: 156-171.
23. + channels after chronic spinal cord injury. Eur J Neurosci 2000, 12: 491-506.
24. Karimi-Abdolrezaee S, Eftekharpour E, Fehlings MG. Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma. Eur J Neurosci 2004, 19: 577-589. (Pubitemid 38241297)
25. McDonald JW, Belegu V. Demyelination and remyelination after spinal cord injury. J Neurotrauma 2006, 23: 345-359. (Pubitemid 43726315)
26. Totoiu MO, Keirstead HS. Spinal cord injury is accompanied by chronic progressive demyelination. J Comp Neurol 2005, 486: 373-383. (Pubitemid 40605041)
27. Wang H, Fu Y, Zickmund P, Shi R, Cheng JX. Coherent antistokes Raman scattering imaging of axonal myelin in live spinal tissues. Biophys J 2005, 89: 581-591. (Pubitemid 41098311)
28. Howell OW, Palser A, Polito A, Melrose S, Zonta B, Scheiermann C, et al. Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis. Brain 2006, 129: 3173-3185. (Pubitemid 44871434)
29. Shi R, Pryor JD. Pathological changes of isolated spinal cord axons in response to mechanical stretch. Neuroscience 2002, 110: 765-777. (Pubitemid 34270546)
30. Waxman SG. Demyelination in spinal cord injury. J Neurol Sci 1989, 91: 1-14. (Pubitemid 19161689)
31. Fu Y, Sun W, Shi Y, Shi R, Cheng JX. Glutamate excitotoxicity inflicts paranodal myelin splitting and retraction. PLoS One 2009, 4: e6705.
32. Fu Y, Wang H, Huff TB, Shi R, Cheng JX. Coherent anti-Stokes Raman scattering imaging of myelin degradation reveals a calcium-dependent pathway in lyso-PtdCho-induced demyelination. J Neurosci Res 2007, 85: 2870-2881. (Pubitemid 47523571)
33. Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol 1981, 313: 301-315. (Pubitemid 11125577)
34. Bostock H, Sherratt RM, Sears TA. Overcoming conduction failure in demyelinated nerve fibres by prolonging action potentials. Nature 1978, 274: 385-387. (Pubitemid 8387340)
35. Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985, 328: 358-361. (Pubitemid 15135163)
36. Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989, 22: 47-52.
37. Blight AR, Gruner JA. Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats. J Neurol Sci 1987, 82: 145-159. (Pubitemid 18001996)
38. Kaji R, Sumner AJ. Effects of 4-aminopyridine in experimental CNS demyelination. Neurology 1988, 38: 1884-1887. (Pubitemid 19004585)
39. Hayes KC, Blight AR, Potter PJ, Allatt RD, Hsieh J, Wolfe DL, et al. Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. Paraplegia 1993, 31: 216-224. (Pubitemid 23264674)
40. Hayes KC. The use of 4-aminopyridine (Fampridine) in demyelinating disorders. CNS Drug Rev 2004, 10: 295-316. (Pubitemid 40128914)
41. Donovan WH, Halter JA, Graves DE, Blight AR, Calvillo O, McCann MT, et al. Intravenous infusion of 4-AP in chronic spinal cord injured subjects. Spinal Cord 2000, 38: 7-15. (Pubitemid 30142551)
42. Halter JA, Blight AR, Donovan WH, Calvillo O. Intrathecal administration of 4-aminopyridine in chronic spinal injured patients. Spinal Cord 2000, 38: 728-732. (Pubitemid 32060052)
43. Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009, 373: 732-738.
44. Targ EF, Kocsis JD. Action potential characteristics of demyelinated rat sciatic nerve following application of 4-aminopyridine. Brain Res 1986, 363: 1-9. (Pubitemid 16148014)
45. Blight AR. Computer simulation of action potentials and afterpotentials in mammalian myelinated axons: the case for a lower resistance myelin sheath. Neuroscience 1985, 15: 13-31. (Pubitemid 15008572)
46. van der Bruggen MA, Huisman HB, Beckerman H, Bertelsmann FW, Polman CH, Lankhorst GJ. Randomized trial of 4- aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol 2001, 248: 665-671. (Pubitemid 32695862)
47. Acorda. Acorda Therapeutics Reports Results of Fampridine-SR Clinical Trials (Press Release). 2004.
48. Potter PJ, Hayes KC, Segal JL, Hsieh JT, Brunnemann SR, Delaney GA, et al. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J Neurotrauma 1998, 15: 837-849. (Pubitemid 28487997)
49. Grijalva I, Guizar-Sahagun G, Castaneda-Hernandez G, Mino D, Maldonado-Julian H, Vidal-Cantu G, et al. Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial. Pharmacotherapy 2003, 23: 823-834. (Pubitemid 36875665)
50. Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW. 4-Aminopyridine in multiple sclerosis: Prolonged administration. Neurology 1991, 41: 1344-1348.
51. Stefoski D, Davis FA, Faut M, Schauf CL. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987, 21: 71-77. (Pubitemid 17004147)
52. Fujihara K, Miyoshi T. The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis. J Neurol Sci 1998, 159: 102-106. (Pubitemid 28365891)
53. Davis FA, Stefoski D, Quandt FN. Mechanism of action of 4-aminopyridine in the symptomatic treatment of multiple sclerosis. Ann Neurol 1995, 37: 684-684.
54. Polman CH, Bertelsmann FW, De Waal R, Van DH, Uitdehaag B, Van Loenen AC, et al. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 1994, 51: 1136-1139. (Pubitemid 24352857)
55. Polman CH, Bertelsmann FW, Van Loenen AC, Koetsier JC. 4-Aminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 1994, 51: 292-296. (Pubitemid 24088417)
56. van Diemen H, Polman CH, van Dongen M, Nauta J, Strijers R, Van Loenen AC, et al. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: A neurophysiological study. J Neurol Sci 1993, 116: 220-226. (Pubitemid 23176860)
57. Bever CT Jr., Young D, Anderson PA, Krumholz A, Conway K, Leslie J, et al. The effects of 4-aminopyridine in multiple sclerosis patients: controlled, crossover trial. Neurology 1994, 44: 1054-1059.
58. van Diemen HAM, Polman CH, van Dongen TMMM, van Loenen AC, Nauta JJP, Taphoorn MJB, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992, 32: 123-130.
59. Davis FA, Stefoski D, Rush J. Orally administered 4- aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990, 27: 186-192. (Pubitemid 20086640)
60. Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983, 60: 353-362. (Pubitemid 13051185)
61. Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006, 111: 224-259. (Pubitemid 43765538)
62. Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008, 71: 1134-1141.
63. Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010, 68: 494-502.
64. Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007, 13: 357-368. (Pubitemid 46705997)
65. Van Diemen HA, Polman CH, Koetsier JC, Van Loenen AC, Nauta JJ, Bertelsmann FW. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 1993, 16: 195-204. (Pubitemid 23149956)
66. Agoston S, Salt PJ, Erdmann W, Hilkemeijer T, Bencini A, Langrehr D. Antagonism of ketamine-diazepam anaesthesia by 4-aminopyridine in human volunteers. Br J Anaesth 1980, 52: 367-371.
67. Pena F, Tapia R. Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamateand GABA-mediated neurotransmission and of ion channels. Neuroscience 2000, 101: 547-561.
68. Pena F, Tapia R. Relationships among seizures, extracellular amino acid changes, and neurodegeneration induced by 4-aminopyridine in rat hippocampus: a microdialysis and electroencephalographic study. J Neurochem 1999, 72: 2006-2014. (Pubitemid 29186004)
69. Stork CM, Hoffman RS. Characterization of 4-aminopyridine in overdose. Clin Toxicol 1994, 32: 583-587. (Pubitemid 24332007)
70. Felts PA, Smith KJ. The use of potassium channel blocking agents in the therapy of demyelinating diseases. Ann Neurol 1994, 36: 454-454.
71. Smith DT, Shi R, Borgens RB, McBride JM, Jackson K, Byrn SR. Development of novel 4-aminopyridine derivatives as potential treatments for neurological injury and disease. Eur J Med Chem 2005, 40: 908-917. (Pubitemid 41376305)
72. McBride JM, Smith DT, Byrn SR, Borgens RB, Shi R. 4-Aminopyridine derivatives enhance impulse conduction in guineapig spinal cord following traumatic injury. Neuroscience 2007, 148: 44-52. (Pubitemid 47211628)
73. Sun W, Smith D, Bryn S, Borgens R, Shi R. N-(4-pyridyl) methyl carbamate inhibits fast potassium currents in guinea pig dorsal root ganglion cells. J Neurol Sci 2009, 277: 114-118.
74. McBride JM, Smith DT, Byrn SR, Borgens RB, Shi R. Dose responses of three 4-aminopyridine derivatives on axonal conduction in spinal cord trauma. Eur J Pharm Sci 2006, 27: 237-242. (Pubitemid 41831259)